{"id":13713,"date":"2024-09-27T09:01:32","date_gmt":"2024-09-27T09:01:32","guid":{"rendered":"http:\/\/medexperts.pro\/?p=13713"},"modified":"2024-09-27T09:26:20","modified_gmt":"2024-09-27T09:26:20","slug":"new-r-s-v-vaccines-had-limited-takers-last-year-will-this-year-be-better","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=13713","title":{"rendered":"New R.S.V. Vaccines Had Limited Takers Last Year. Will This Year be Better?"},"content":{"rendered":"
<\/div>\n

Some of the problems that patients ran into, including a lack of insurance coverage, have been resolved.<\/p>\n

\n
\n
\n

When the Food and Drug Administration approved several new vaccines against respiratory syncytial virus last year, the shots were celebrated as a \u201cpowerful new tool\u201d to protect infants and older people. Pharmaceutical giants projected billions of dollars in sales, assuming a large swath of the eligible population would roll up their sleeves.<\/p>\n

But for all the anticipation, relatively few people sought the vaccines out: Only about 24 percent of eligible older adults received it last season. It was a disappointing response, one experts blamed largely on vaccine fatigue, the cost of the shots and confusion over who should get them.<\/p>\n

This season, however, promises to be different. Drugmakers have ramped up manufacturing of a treatment for infants that was in short supply last year, and more insurers are now covering R.S.V. shots. But experts said there are still hurdles that must be overcome to increase vaccination rates, including sharpening public health messaging and increasing the public\u2019s understanding of how serious the virus can be for certain groups.<\/p>\n